GENE ONLINE|News &
Opinion
Blog

China
Sanofi Invests in Innovent to Gain Stronger Foothold in China
2022-08-05
Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe
2022-07-18
Zhiyi Biotech Finishes Series B Funding With $45 Million For Live Biotherapeutics
2022-07-11
Brii Biosciences Begins Marketing COVID-19 Antibody Cocktail Therapy in China
2022-07-07
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Innovent, Lilly’s PD-1 Inhibitor Approved to Treat Esophageal Cancer in China
2022-06-21
Shenzhen Joincare Plots $300 Million IPO On Swiss Exchange
2022-06-20
Organon Licenses Biosimilars From Shanghai’s Henlius For $103 Million
2022-06-14
Everest Medicines Secures Breast Cancer Drug Approval in China
2022-06-13
Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug
2022-06-06
China’s Hengrui Buds Off New Biotech With 11 Therapeutic Programs
2022-05-19
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
Backed by RTW, LENZ Therapeutics Inks $110 Vision Loss Pact with China’s JIXING
2022-04-14
Shanghai’s Hasten Seals $322 Million Acquisition of Takeda Drugs
2022-04-06
Kintor Pharma’s Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
2022-04-05
1 2 3 6
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!